Ronald E. White, Ph.D.
Ron White received a Ph.D. in Organic Chemistry from the University of Wisconsin in 1974 and completed post-doctoral training in biochemistry of the CYP enzymes at the University of Michigan. He has held various positions of increasing responsibility in the pharmaceutical industry, including Vice-President of Drug Metabolism and Pharmacokinetics at the Schering-Plough Research Institute in Kenilworth NJ and Distinguished Research Fellow at Bristol-Myers Squibb in Princeton, NJ. During his pharmaceutical career, Ron contributed to the development of Clarinex® (desloratadine), Dulera® (mometasone/formoterol combination), Noxafil® (posaconazole), PEG-Intron® (pegylated interferon-alpha), Temodar® (temozolomide), Victrelis® (boceprevir), Zontivity® (vorapaxar), Vytorin® (ezetimibe/simvastatin combination), and Zetia® (ezetimibe).
Ron is a past member of the Drug Metabolism Technical Group of Pharmaceutical Research Manufacturers of America and was Chair of the Gordon Research Conference on Drug Metabolism. He is presently a member of the Editorial Board of the journal Drug Metabolism and Disposition and Adjunct Professor of Chemical Biology in the Rutgers University School of Pharmacy. He is a member of several scientific societies, including the American Chemical Society, the American Association of Pharmaceutical Sciences, the American Society for Biochemistry and Molecular Biology, and the International Society for the Study of Xenobiotics.
Ron has consulted for the U.S. Food and Drug Administration and the National Institutes of Health, as well as the Michael J. Fox Foundation for Parkinson’s Research. He has lectured and published extensively in the areas of drug metabolizing enzymes, pharmacokinetics and drug discovery and is the holder of five United States patents.
Ron is a past member of the Drug Metabolism Technical Group of Pharmaceutical Research Manufacturers of America and was Chair of the Gordon Research Conference on Drug Metabolism. He is presently a member of the Editorial Board of the journal Drug Metabolism and Disposition and Adjunct Professor of Chemical Biology in the Rutgers University School of Pharmacy. He is a member of several scientific societies, including the American Chemical Society, the American Association of Pharmaceutical Sciences, the American Society for Biochemistry and Molecular Biology, and the International Society for the Study of Xenobiotics.
Ron has consulted for the U.S. Food and Drug Administration and the National Institutes of Health, as well as the Michael J. Fox Foundation for Parkinson’s Research. He has lectured and published extensively in the areas of drug metabolizing enzymes, pharmacokinetics and drug discovery and is the holder of five United States patents.